THALIDOMIDE | N020785 | BRISTOL-MYERS SQUIBB CO
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
CELGENE CORPORATION v. HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED et al 9 patentsANDA 211947thalidomide | D.N.J. | 2018-08-31 | Terminated 2019-09-18 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Celgene Corporation - Citizen Petition FDA-2007-P-0113 · 6 docket documents Celgene Corporation filed this citizen petition on September 20, 2007, requesting that the FDA refrain from approving Barr Laboratories' ANDA 78-505 for a generic thalidomide product for treating erythema nodosum leprosum, citing unacceptable safety risks and violation of Celgene's orphan drug exclu | 505(q) | 2008-04-28 | Denied | — |
State of Connecticut FDA-2005-P-0004 · 50 docket documents This document is not a citizen petition to the FDA; it is a corporate brochure or annual report from Celgene Corporation describing its cancer drug pipeline and business achievements as of 2003. The document presents information about Celgene's marketed product THALOMID (thalidomide) and investigati | Other | 2005-05-04 | Granted | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.